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Background: Interventions for alcohol use disorders (AUDs) in HIV infected individuals have been primarily
targeted at HIV risk reduction and improved antiretroviral treatment adherence. However, reduction in alcohol use
is an important goal. Alcohol use affects other key factors that may influence treatment course and outcome. In this
study the authors aim to administer an adapted intervention for AUDs to reduce alcohol use in people living with
HIV/AIDS (PLWHA).
Methods: This study is a cluster randomised controlled trial at 16 HIV care clinics. A motivational interviewing and
cognitive behavioural therapy based intervention for AUDs, developed through adaptation and piloted in Zimbabwe, will
be administered to PLWHA with AUDs recruited at HIV clinics. The intervention will be administered over 16 sessions at 8
HIV clinics. This intervention will be compared with an equal attention control in the form of the World Health
Organization Mental Health Gap Action Programme (WHO mhGAP) guide, adapted for the Zimbabwean context. General
function, quality of life, and adherence to highly active antiretroviral treatment (HAART) will be secondary outcomes.
Booster sessions will be administered to both groups at 3 and 6 months respectively.
The primary outcome measure will be the Alcohol Use Disorder Identification Test (AUDIT) score. The World Health
Organisation Disability Assessment Schedule 2.0 (WHODAS 2.0), World Health Organisation Quality of Life (WHOQoL) HIV,
viral load, and CD4 counts will be secondary outcome measures. Outcome assessments will be administered at baseline,
3, 6, and 12 months. Moderating factors such as perceived social support, how people cope with difficult situations and
post-traumatic exposure and experience will be assessed at baseline. Trained research assistants will recruit participants.
The outcome assessors who will be trained in administering the outcome and moderating tools will be blinded to the
treatment arms allocated to the participants. However, the principal investigator, participants and intervention staff will be
unblinded.
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Data will be analysed using STATA Version 14. Primary and secondary outcomes will be measured at four time points that
is; at baseline, 3, 6, and 12 months respectively. All participants will be included in the analysis of primary and secondary
outcome measures. The mean AUDIT scores will be compared between groups using student t-tests. Multilevel logistic
regression analysis will be performed for binominal variables and multilevel linear regression for continuous variables.
Descriptive statistics will be computed for baseline and follow-up assessments.
Discussion: The study will be the first to address problematic alcohol use in PLWHA in Zimbabwe. It seeks to use local
resources in delivering a modified, brief, evidence-based, and culturally contextualised intervention. The study results will
determine the effectiveness of adapting psychological interventions for AUDs in HIV infected adults using a task-sharing
framework.
Trial registration: Pan African Clinical Trial Registry, PACTR201509001211149. Registered 22 July 2015.
Keywords: Alcohol use disorders, Motivational interviewing, Cognitive behavioural therapy, Intervention, ZimbabweBackground
According to the World Health Organization (WHO), alco-
hol abuse is one of the top three causes of health related
problems apart from child underweight and unsafe sex [1].
In low and middle income countries, AUDs cause 19.5 mil-
lion Disability Adjusted Life Years (DALYS) [2]. Harmful al-
cohol use results in 3.3 million deaths per year globally. In
2012, according to WHO alcohol use contributed 5.1% to
the global burden of diseases or 139 million net DALYS.
Zimbabwe is a country with one of the highest per capita
alcohol consumption rates in the WHO Afro-Region at
5.7 l per capita per year in 2010 [3].
Alcohol consumption is high among people living with
HIV/AIDS (PLWHA) especially hazardous alcohol con-
sumption and this is associated with decreased survival
[4]. Studies have also shown that alcohol consumption is
linked to HIV infection, adherence to the highly effective
antiretroviral therapy (HAART), HIV prevention, de-
layed testing and treatment, and general poor outcome
in HIV care and treatment [5, 6]. PLWHA are at in-
creased risk of physiologic injury such as liver disease
from alcohol [7].
Heavy episodic drinking is common in sub-Saharan
Africa, the epicentre of the HIV pandemic [8]. The quantity
of alcohol consumed is more closely related to HIV infec-
tion than the frequency although some studies have indi-
cated that the drinking context is as important [9]. In
addition to alcohol and other drug abuse, depression, anx-
iety and psychosis, are linked to non-adherence to HAART
and to treatment interruptions [10–12]. In order to achieve
adequate viral suppression and improve adherence to
HAART, AUDs and other psychiatric disorders need to be
appropriately treated. Wu et al., after controlling for adher-
ence, showed that daily consumption of alcohol was associ-
ated with a viral load increase, while reduction of alcohol
intake to once weekly intake was associated with a reduc-
tion in viral load [13].
There is evidence that alcohol affects the functioning of
the human immune system negatively [14]. Alcohol hasbeen shown to increase the concentration of HIV RNA in
semen and the vagina [15]. There is also some evidence
that vaginal shedding of viral RNA is increased by alcohol
which is associated with increased infectiousness [16].
AUDs and low adherence to HAARTare associated with
poor health outcomes and quality of life [17, 18], while
simplification of HAART has been associated with im-
proved adherence and quality life [19, 20]. Alcohol con-
sumption has implications for HIV treatment through
direct toxic effects on the liver and the interactions with
HAART [21, 22].
Despite the high prevalence of alcohol use disorders
among people living with HIV/AIDS (PLWHA) and the
potential for adverse health consequences, there is not
enough contextual evidence for behavioural interven-
tions for AUDs in African settings. Motivational inter-
viewing (MI), cognitive behavioural therapy (CBT),
problem solving, and risk reduction are some of the
evidence-based treatments that have been used to treat
alcohol use disorders [23]. MI and CBT have been used
both in combination and separately [24].
Sub-Saharan Africa suffers from the world’s most pro-
nounced crisis in terms of human resources for health [25].
A streamlined and rationalized chain of care that relieves
pressure on individual workers is needed. However this
chain of care for patients, while increasing access to and
uptake of interventions, must be quality assured [26]. Up
skilling various cadres of staff to provide services that are
normally delivered by highly skilled workers is recom-
mended [27]. Task sharing has been proposed as an ap-
proach to provide services that are normally provided by
highly skilled staff by the lesser skilled through training and
provision of treatment manuals. For task-sharing to work,
attention needs to be paid to the selection of staff, their
current workload, the adequacy of training, and the avail-
ability of manualised interventions [28]. Supervision and
support visits are essential for quality control and maintain-
ing fidelity [29]. Task-sharing has the potential to build cap-
acity and integrate HIV care, thereby also addressing the
Madhombiro et al. BMC Psychiatry  (2017) 17:44 Page 3 of 13gap that results from health worker attrition due to immi-
gration and HIV [30].
Most studies on HIV in Zimbabwe have focused on be-
havioural change with particular emphasis on risk reduc-
tion and adherence to HAART. There have been no
studies of the management of AUDs among PLWHA in
Zimbabwe. This is to our knowledge, the first intervention
study that specifically targets AUDs in PLWHA. This
intervention for AUDs intervention will be compared with
the mhGAP intervention guide alcohol use management
module which is a part of the WHO Mental Health Gap
Action Programme (WHO mhGAP) [31]. The mhGAP
intervention guide was developed for primary care settings
and has been used in developing countries for the identifi-
cation and management of various mental and neuro-
logical and substance use disorders (MNS).
Methods/Design
Preparatory-work
In the development of the intervention for the proposed
study, a literature review was undertaken to evaluate the
available scientific evidence on the magnitude of the AUDs
in PLWHA across Low and Medium Income Countries
(LMIC). The review of literature for efficacy and effective-
ness studies was focused on relevant socio-demographic
variables (including gender), methods used, HIV disease
progression and alcohol outcomes. This evidence was thenFig. 1 Intervention preparatory stagespresented to experts and HIV specialists to bring their at-
tention to the problem and get them on board to expand
on the work and bring in local context. The study flow is
shown in Fig. 1.
Focus in the development of this intervention was on
integration and adaptation of MI and CBT, which were
the main intervention theoretical frameworks and brought
in the local contextual framework. Development of treat-
ment manuals, and exploratory work with a small number
of patients then followed. The intervention development
and design included meetings and workshops that were
qualitative in nature. This involved experts such as provin-
cial medical officers, district medical officers, nurses, and
stakeholders from community leadership and provincial
government, NGOs and alcohol service organizations
such as the alcoholics anonymous and PLWHA. Interac-
tions and formal meetings with the Ministry of Health,
College of Health Sciences (Departments of Medicine,
Psychiatry and Community Medicine) were done to gather
their views. The National AIDS Council, which is the
statutory body mandated with planning, coordinating, and
evaluation of HIV/AIDS activities in Zimbabwe partici-
pated in the development of the intervention.
Focus group discussions, which were conducted with
PLWHA, were around the language of alcohol and
knowledge gaps concerning alcohol use. Barriers and facili-
tators of AUDs treatment were explored. Issues around
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leaflet were discussed as well.
The current HIV clinic setup, existing staff skills in
counselling and established counsellor-patient relation-
ships was identified as the main facilitators to interven-
tion. Stigma, lack of skills among health professionals,
absence of brief culturally appropriate screening tools,
and patient and provider attitudes toward their own al-
cohol use were identified as the main barriers. The pilot
study showed that the RGNs could deliver the interven-
tion. The recruitment and retention of participants was
feasible and adjustments to the study instruments
needed to be done to allow smooth flow of the study.Aims
1. To evaluate the effectiveness through a cluster
randomized controlled trial of an adapted MI/CBT
AUDs intervention in PLWHA.
2. To assess the impact of the AUDs intervention on
adherence to HAART as measured by viral load and
CD4 count, functional capacity as measured by the
WHODAS 2.0, and quality of life as measured by
the WHOQoL HIV.
3. To identify the moderators between alcohol and
HIV treatment using the Cope-13, Multidimensional
Scale of Perceived Social Support (MSPSS and the
Davison Trauma Scale (DTS).Design
Two-arm cluster randomised controlled trial at 16 HIV
clinics in Zimbabwe, with the unit of randomization
HIV clinics, comparing Motivational Enhancement
Therapy and Cognitive Behavioural Therapy from Pro-
ject MATCH adaptation based treatment, with the
WHO mhGAP intervention guide, adapted for the local
context. This design has been selected to increase ad-
ministrative efficiency and decrease the risk of experi-
mental contamination at clinic level. The registered
general nurses (RGNs) will be trained to administer the
intervention and control using manuals.Study setting
The study will be conducted in HIV clinics in Zimbabwe,
a sub-Saharan African country with an estimated 1,6
million PLWHA whose HIV care is decentralised. RGNs
run the HIV care clinics and physicians provide supervi-
sion. RGNs provide HIV testing, adherence counseling
and monitor treatment progress. The patients are
reviewed, largely for reboarding of their medication.
There is an electronic database of all the patients at
every clinic.Participants
Participants are treatment-seeking adults who are HIV




Socio-demographic data such as gender, age, marital sta-
tus, employment and years of education will be collected.
Clinical data
Clinical data such as the date of HIV testing, duration
on HIV treatment, treatment regimen, CD4 count and
viral load will be collected.
Primary outcome tools
The primary outcome measures will be the change in al-
cohol use as measured by AUDIT score change from the
baseline. Although alcohol use biomarkers would have
been ideal, due to resource constraints a self-report tool
will be used in this study.
Alcohol Use Disorder Identification Test (AUDIT) [32]
The AUDIT has not been validated in Zimbabwe, how-
ever several studies have utilized the AUDIT as an in-
strument to assess alcohol use in various communities
including Zimbabwe [33]. In a study by Bush et al. [34]
the AUDIT was found to have a sensitivity of 89% and a
specificity of 67%. The unit of alcohol as defined in the
AUDIT is 10 g. The legislation requires that the percent-
age of alcohol in alcoholic beverages be specified and
follow the regional norm. The alcohol quantity in grams
is however more informative. A traditional brew in the
rural areas of Zimbabwe, which has 40 g of alcohol in
1.5 l, is estimated to have 4 units of alcohol and will be
used to assess the quantity of units consumed according
to local norms.
Secondary outcome tools
The secondary outcomes will be the functional capacity,
the quality of life and adherence to HAART.
World Health Organisation Disability Assessment Schedule
2.0 (WHODAS 2.0) [35]
The WHODAS 2.0 will be a secondary outcome meas-
ure and will be administered at baseline, 3, 6, and
12 months respectively to assess functional capacity. The
WHODAS 2.0 contains 6 domains, which are cognition,
mobility, self-care, getting along, life activities and par-
ticipation. It is fairly short and simple and takes about
5–20 min to administer. Although the WHODAS 2.0
has not been validated in Zimbabwe, it has been used in
HIV patients in South Africa [36].
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The WHOQoL HIV is a tool that assesses the quality of
life of persons with HIV. The WHOQoL HIV has six
domains that include physical, psychological, level of
independence, social relationships, environment, and
spirituality domains (http://www.who.int/msa/qol/). In a
study to assess the overall health-related quality of life in
a sample of HIV infected South Africans, results showed
that quality of life, as measured by WHOQoL, was poor,
with further analysis showing that the WHOQoL do-
mains predicted overall quality of life in PLWHA [38].
Although the WHOQoL has not been validated in
Zimbabwe, the Department of Psychiatry, University of
Zimbabwe was involved in its development and the tool
has been used in the region [39].
Tools for confirming eligibility
The tools to confirm eligibility will assess the presence
of other drug use and exclusion of participants with de-
mentia and other psychiatric conditions.
Drug Use Disorders Identification Test (DUDIT) [40]
The DUDIT screens for the presence of substances of
abuse other than alcohol [41]. The DUDIT has validity in
determining the severity of dependency although caution
needs to be exercised in deciding on cut- off points [42].
In a study in the USA the assessment of its psychometric
properties, the DUDIT had a sensitivity and specificity of
90% and 80%, respectively, with an optimal cut-off of 8
[43]. The DUDIT has not been validated in Zimbabwe.
Substance Abuse Mental Illness Symptom Screener
(SAMISS) [44]
The SAMISS identifies individuals with substance abuse
and mental illness. It can be simply scored and assists in
the identification of patients with probable mental ill-
ness. The SAMISS has been validated in South Africa
and has been identified as a tool that can be used in pri-
mary care settings for PLWHA [45]. The SAMISS was
found to have a sensitivity of 94% and a specificity of
58% and was better at identifying alcohol use (sensitivity
94% and specificity 85%) and mental illness (sensitivity
97% and specificity 60%) [45]. However, it has not been
validated in Zimbabwe.
M.I.N.I (MINI International Neuropsychiatric Interview 7.0 [46]
The M.I.N.I for the DSM-5 is the gold standard diagnos-
tic interview in this study and will be administered by a
clinician [47]. The clinician-administered M.I.N.I. will be
used to assess for common psychiatric disorders. The
M.I.N.I has been recognised as a short diagnostic inter-
view that can be easily incorporated into routine clinical
assessment [48].International HIV Dementia Scale (IHDS) [49]
Patients with dementia will be excluded and referred for
specialist care, as they may not be able to cognitively en-
gage with the requirements of the intervention. The
IHDS has not been validated in Zimbabwe, but has been
used in sub-Saharan Africa samples. In cohorts in USA
and Uganda, the sensitivity and specificity using cut-off
of 10 or less were 80 and 57% in the USA and 80 to 55%
in Uganda [50].
Additional assessments/ moderators
These tools assess the factors that may be related to al-
cohol use and HIV treatment such as history of trauma,
social support and coping with stress.
Davidson Trauma Scale (DTS) [51]
The DTS will be used to determine the presence of trau-
matic event exposure and possible posttraumatic stress
symptoms. HIV is associated with traumatic experiences
and features of post-traumatic stress disorder (PTSD).
The Davidson Trauma Scale was developed as a self-
rating tool which has been shown to be useful in diag-
nosing and measuring symptom severity and treatment
outcome in PTSD [52].
COPE-13 [53]
This instrument assesses how people respond to difficult
or stressful events in their lives. The COPE-13 was de-
veloped to assess situational and dispositional coping
styles and has been used in different samples in commu-
nities affected by natural disasters in caregivers and pa-
tients [54].
Multidimensional Scale of Perceived Social Support
(MSPSS) [55]
The MSPSS aims to assess the social support available to
the patient from significant others, family and friends.
Social support can act as a buffer for psychological dis-
tress whilst the lack of it can lead to adverse outcomes
such as relapse into depression and emotional distress in
physical illness [56]. The MSPSS has been shown to be
reliable and valid in some populations (e.g. in the Thai
population) but has not been validated in Zimbabwe.
Procedures
Intervention
The intervention will be blended motivational interview-
ing (MI) and cognitive behaviour therapy (CBT). The
four key principles of MI which are to (a) express em-
pathy, (b) develop discrepancy, (c) roll with resistance,
and (d) support self-efficacy will be employed in this
intervention. MI topics will help in building client mo-
tivation and emphasize responsibility for change. The
provider gives guidance and support with no specific
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tive behavioural therapy will include (a) identifying intra-
personal and interpersonal triggers for relapse, (b)
coping-skills training, (c) alcohol refusal skills training,
(d) functional analysis of alcohol use, and (e) increasing
non-drinking related activities.
The intervention will have 16 sessions. Eight sessions
will be given at baseline and 4 each at 3 and 6 months.
Sessions 1, 4, 6 and 7 will be repeated at 3 and 6 months.
Additional sessions, with content dependent on individual
problems identified, will be administered. The content of
the intervention is shown in Fig. 2.
Control
An adapted version of the mhGAP intervention guide
(the alcohol section) will be administered to participantsFig. 2 Intervention sessions, expected time and goalsat 8 clinics. The session will also focus on providing
feedback on the AUDIT score, the CD4 count, viral load,
and on functioning and quality of life. This intervention
is expected to last one hour (based on our experience in
the pilot study). At 3 and 6 months, the control inter-
vention will be re-administered and outcomes assessed
with the final assessment done at 12 months.
Training
The principal investigator will be the chief trainer on the
MI/CBT AUDs intervention while a co-investigator
trained in the mhGAP intervention guide will train the
control arm interventionists.
RGNs will be trained in the use of the intervention
(MI/CBT) and control (mhGAP) manuals. Sixty-four
nurses working at 16 HIV Care clinics will be trained.
Madhombiro et al. BMC Psychiatry  (2017) 17:44 Page 7 of 13Material covered in the training manual will include
evidence-based interventions for co-occurring HIV and
AUDs, administration of the AUDIT and other data
gathering tools, the theoretical basis of the intervention,
counselling skills and supervision. Further, RGNs will re-
ceive training in good clinical practice, covering research
ethics, the importance of maintaining confidentiality,
reporting adverse events, the intervention protocol, and
the process of referring patients for specialized care.
Practical exercises will include self-administered quizzes,
small group discussions, and case study exercises.
Training materials developed during the preparatory
phase of the study will be used in the intervention and
control training. RGNs who were identified and trained
for the pilot study will be recruited for the training. Staff
trained in the feasibility study, who are RGNs by profes-
sion, will do supervisory visits. Supervisors will use super-
vision protocols developed for the study. Supervisory
visits will be undertaken at 3, 6 and 12 months. The ability
to follow essential elements of the intervention manual as
judged in a meeting of supervisors through the review of
audio and videotaping will be the standard of practice.
Further, trained intervention staff will be required to take
a written test covering the content of the intervention and
control manual and attain a pass mark of 50%.
Participants
Recruitment
The selected 16 HIV clinics will be requested to provide
patient registration numbers, which will then be entered
into a remote computer to randomly select participants
for screening for study eligibility. Consenting patients will
be screened with the AUDIT for eligibility. A cut-off of 6
for females and 7 for males will be used [57]. The recruit-
ment procedure and study flow are shown in Fig. 3.
Inclusion criteria
Study participants, aged 18 years and older, will be drawn
from PLWHA on HAART receiving services from HIV
care clinics in Zimbabwe. To be eligible, participants need
to have been on HAART for at least three months and
must be regular clinic attenders to reduce loss to follow up.
Exclusion criteria
Participants who are on treatment for alcohol depend-
ency, other primary drug use disorder, and those with
primary psychiatric disorder or dementia will also be ex-
cluded and referred to the psychiatrist for further assess-
ment and care.
Outcome measures
The primary outcome measure will be the AUDIT score.
This will measure the effect of the intervention on
drinking. Secondary outcome measures will comprisescores on the WHODAS 2.0, WHOQoL HIV, CD4
count and viral load. Research assistants who are gradu-
ates in health and social sciences will be trained to ad-
minister the outcome assessments. The training will
include the scoring of the AUDIT, the WHODAS and
the WHOQoL HIV.
Fidelity
Fidelity has four defined components: design of the
intervention, training in the intervention, monitoring the
delivery of the intervention and monitoring its receipt.
As it is essential to maintain fidelity, the treatment will
be manualised and intervention staff will be appropri-
ately trained to adhere to the treatment guides. Training
in the intervention includes role-playing, which facili-
tates competence in the delivery of the intervention. As
part of the training, an intervention training manual has
been developed that will be used in the intervention and
controls. Delivery of the intervention will be monitored
through patient cards and video and audio recordings of
patient session. Supervision will also be used to maintain
fidelity. The standard operating procedures will contain
supervision protocols. The receipt of the intervention
will be monitored through patient record cards and in-
terviews. Overall fidelity will be assessed with a compre-
hensive intervention fidelity guide (CIFG) [58].
Randomization
A computer generated block randomization will be used
to assign clinics to either intervention or control arm (as
shown in Fig. 4).
Allocation concealment
A statistician on the study based in South Africa will
maintain concealment of allocation.
Blinding
Participants will not be blind to treatment. Research as-
sistants who administer the outcome measures will be
blinded to the assignment of clinics to intervention and
control. Blinding will be achieved by retaining the same
assessors at a site from the baseline, the 3,6 and
12 months assessments. In order to minimise assessment
bias, assessors will not have access to the data collected
at previous assessments. The Principal Investigator will
be not be blinded to clinic status as he will be a trainer
on the interventions.
Visits
At the baseline visit, the AUDIT, DUDIT, SAMISS, IHDS,
WHOQoL HIV and WHODAS 2 will be administered.
The AUDIT, WHOQoL HIV, and WHODAS will be ad-
ministered at 3, 6, and 12 months. The CD4 count and
viral load will be measured at baseline, 3, 6 and 12 months
Fig. 3 Identification of clusters and recruitment of participants
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Fig. 4 Procedure and study flow diagram
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Davison Trauma Scale will assess social support, coping
and resilience at baseline and 12 months, and included as
moderator variables in the analysis
Statistical analysis
Sample size
A meta-analysis suggested that a clinically significant dif-
ference in negative status on the AUDIT between brief
intervention and control of 13% [59]. Shersten et al. [60]
describe intra-cluster correlation coefficient in human
subjects to be between 0.01 and 0.02 and assumed the
intra-cluster correlation in this study to be 0.02. A total of
16 clusters (8 clusters per group) to achieve 80% power to
detect a mean difference of 2.5 (with precision of ± 0.45)
between the treatment condition means when the stand-
ard deviation within a cluster is 4 and the intra-cluster
correlation are 0.02 and a significance level of 0.05.
An estimated sample size of 180 patients (90 in the
intervention group and 90 in the control group) will be
required to detect a difference of 13% between interven-
tion and control groups taking into account the design
effect of 1.56. Assuming an attrition rate of 30% (as
identified in the pilot study), a total sample size of 240
will be required. Fifteen participants will be randomlyselected (with equal probability) at each clinic from a pa-
tient number list.
Analysis of covariance (ANCOVAs) and mixed effects
linear regression models will be performed for all continu-
ous variables. Generalised linear mixed effects logistic re-
gression model will be performed for binary outcomes. All
analyses will allow for within-clinic clustering.
Management of missing data
Intention to treat will be the principle of statistical
analysis.
Clinic level
All clinics randomized at cluster level will be analysed
by the treatment arm allocated at randomization.
Participant level
All participants in the study will be included in the ana-
lysis of primary and secondary outcomes.
Analysis approach
Data will be analysed using STATA Version14 [59]. Pri-
mary and secondary outcomes will be measured at four
time points: baseline, 3, 6, and 12 months. To account
for the stratified cluster trial design, the repeated binary
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comes, as well as missing data at follow-up, a General-
ized Estimation Equations (GEE) approach will be used.
Descriptive statistics will be computed for baseline and
follow-up assessments. The mean AUDIT scores will be
compared using student t-tests. Multilevel logistic re-
gression will be performed for binominal and multilevel
linear regression for continuous variables.
Ethics
In order to promote quality control and quality assur-
ance of the study, research staff and the principal inves-
tigator will receive training in research ethics and good
clinical practise. A data research coordinator will ensure
accurate data collection and the secure transfer and stor-
age of electronic data. Weekly feedback meetings will be
held with study personnel, the data manager, and the
project coordinator to address problems and study-
related queries.
Confidentiality
Participants will be assured of the confidential nature of
the study. Anonymity will be maintained by de-identifying
collected data and participants will be identifiable by
unique identifier codes. Patient-level data will be stored
securely on a computer encrypted and password protected
for the study team. Files will be stored in a locked cabinet
at the University of Zimbabwe College of Health Sciences,
Department of Psychiatry for five years.
Risks and discomfort
Although no adverse effects are anticipated, participants
who experience discomfort or who wish to withdraw for
any other reason will be free to do so. Participants who
become distressed and uncomfortable with answering the
assessment questions which address sensitive topics such
as alcohol use and non-adherence and when providing
blood samples for CD4 counts and viral loads will be re-
ferred to a psychiatrist for further care. Participants will
be free to leave the study at any point without prejudice.
Interim analysis
Interim statistical analysis will be carried out at 3 and
6 months. A Data and Safety Monitoring Board (DSMB)
comprising of experts in HIV/AUDS, an independent
statistician and a bioethicist, and the MRCZ will review
study-related concerns (e.g. adverse events) that arise.
They will review study protocols and procedures (e.g.
data collection and storage), as they deem necessary dur-
ing the data collection phase. Safeguards will be imple-
mented throughout the project to protect participant
confidentiality, as described and required by the moni-
toring board, and to minimize the risk of potential phys-
ical and psychological harms.Costs and compensation
Participants will be reimbursed for transport costs and
refreshments (US$3) for each visit.
Benefits
Participants may directly benefit from the interventions.
Any individual identified as alcohol dependent will be
referred for alcohol treatment services. Individuals
assigned to the MI/CBT intervention may reduce their
alcohol consumption, in turn improving HAART adher-
ence and HIV disease outcomes. Clinic staff will benefit
as they will be trained in delivering the intervention
aimed at reducing harmful/hazardous alcohol consump-
tion. Finally, substantial public health knowledge will
likely be gained from this search.
Discussion
In this study it is hypothesized that an adapted MI/CBT
intervention will lead to a significant reduction in alco-
hol use in PLWHA. It is further hypothesized that re-
duction in alcohol use will lead to improved function as
measured by the WHODAS 2.0, improved quality of life
as measured by the WHOQoL HIV, and improved ad-
herence to HAART as measured by the CD4 and viral
load. This study further seeks to establish whether regis-
tered general nurses in primary health care facilities in
Zimbabwe will be effective in providing the MI/CBT
intervention to reduce alcohol use and improve patient
engagement with treatment.
We will test the effectiveness of an MI/CBT interven-
tion that can be used by RGNs for alcohol reduction in
PLWHA. If successful, the intervention will be imple-
mented in HIV clinics in Zimbabwe and other settings
where general nurses oversee HIV treatment. We
hypothesize that patients may view their ability to return
to work as important and this may motivate them to ad-
here to the treatment. Improved quality of life has been
shown to improve adherence in other studies.
Given that most behavioural interventions for alcohol
use have been developed within a Western framework,
the use of an adapted intervention in this study will in-
form us about its effectiveness in reducing alcohol use in
PLWHA in a resource limited setting. In resource rich
environments, inpatient and outpatient services for ad-
dictions are usually widely available. However, in
Zimbabwe, as in many other resource-limited settings,
inpatient management of AUDs may be unaffordable for
the majority. Outpatient care, if available, is the rule ra-
ther than the exception.
To the authors’ knowledge, no published study from
Zimbabwe has examined functioning and quality of life
in PLWHA with AUDs. Improvement in functioning
and quality of life are key aspects to address in this
population. Quality of life has been shown to improve
Madhombiro et al. BMC Psychiatry  (2017) 17:44 Page 11 of 13upon initiation of HAART (http://www.stata.com) and
studies in other countries have documented an improve-
ment in adherence with an improvement in quality of
life [61]. Over a quarter of 15–49 year olds in sub-
Saharan Africa are living with AIDS [62]. Given that this
is the most productive age group in the community, im-
proving functioning will likely have positive socio-
economic impacts on the community.
There are few limitations that warrant mention. Firstly,
we will use a self-report screening measure of drinking.
Self-report may not accurately reveal drinking quantity
and behaviour. That said, the AUDIT has excellent sensi-
tivity and specificity and cross-cultural applicability and
can be used in remote areas where sampling for alcohol
biomarkers may be challenging. Secondly, brief interven-
tions have been shown to be more useful when provided
at community level although the lack training often ham-
pers provision at community level. Thirdly, viral suppres-
sion may not correlate well with adherence; even in
resource rich settings viral suppression can be low despite
an adherence of 80–95%. In this study viral load will be a
proxy measure of adherence. CD4 count in addition to the
viral load will be used as a measure of adherence.
This is a task-sharing intervention study. It is hoped
that, upon successful completion of this study, RGNs
from district hospitals and municipal health facilities will
be trained in recognising and managing AUDs in HIV
infected patients.Abbreviations
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